Figures & data
Figure 1. NO-nps clinically accelerate the clearance of intramuscular abscesses. Induced MRSA abscesses in Balb/c mice were evaluated clinically on day 4 following infection. The four images, (A) untreated, (B) vancomycin treated, (C) NO-np TP treated and (D) NO-np IL, are representative of the clinical appearance of these lesions. Arrows indicate abscesses.
Figure 2. NO-nps effectively kill MRSA and limit muscular infection damage. (A) Histological analysis of Balb/c mice untreated, Vancomycin treated, NO-np TP treated, and NO-np IL treated MRSA-infected intramuscular abscesses on day 4. Mice were intramuscularly infected with 107 MRSA. Representative H&E-stained sections of the skin lesions are shown with the Scale bars: 4X: 25 mm; 10X: 10 mm. (B) Abscess bacterial burden (CFU; colony forming units) in mice infected subcutaneously with 107 MRSA and treated with NO-np is significantly lower than untreated or np-treated mice (n = 12 abscesses per group) as well as vancomycin treated. The percent survival at days 4 (a) and 7 (b) was tabulated based on CFU/gm abscess and compared with control. Error bars denote standard deviations. Symbols denote P value significance calculated by analysis of variance and adjusted by use of the Bonferroni correction. *p = 0.0001, for comparisons of NO-np IL or TP compared with vancomycin. ϕp = 0.001, for comparison of NO-np IL to NO-np TP at day 4. #p = 0.045, for comparison of NO-np IL to NO-np TP at day 7.
